{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:38:50Z","timestamp":1777426730998,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003508","name":"Universitat de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ejim.2020.04.036","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T01:40:29Z","timestamp":1587692429000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-4208","authenticated-orcid":false,"given":"Fabian","family":"Sanchis-Gomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/713609328","article-title":"(a): an emerging cardiovascular risk factor","volume":"40","author":"Lippi","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ejim.2020.04.036_bib0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013The LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"6144","key":"10.1016\/j.ejim.2020.04.036_bib0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.036_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","article-title":"(a): from ancestral benefit to modern pathogen?","volume":"93","author":"Lippi","year":"2000","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.036_bib0005","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1194\/jlr.D800050-JLR200","article-title":"Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR","volume":"50","author":"Lanktree","year":"2009","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.036_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ejim.2020.04.036_bib0008","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European atherosclerosis society consensus panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ejim.2020.04.036_bib0009","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.04.036_bib0010","author":"Langlois","year":"2019","journal-title":"Clin Chem Lab Med."},{"issue":"6","key":"10.1016\/j.ejim.2020.04.036_bib0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10408363.2016.1188055","article-title":"Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions","volume":"53","author":"Kotani","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3\u20134","key":"10.1016\/j.ejim.2020.04.036_bib0012","first-page":"143","article-title":"Lipoprotein (a) and risk of cardiovascular disease\u2013a systematic review and meta analysis of prospective studies","volume":"57","author":"Genser","year":"2011","journal-title":"Clin Lab"},{"key":"10.1016\/j.ejim.2020.04.036_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","article-title":"The relationship between LP(a) and CVD outcomes: a systematic review","volume":"15","author":"Forbes","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.036_bib0014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HCO.0000000000000628","article-title":"The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies","volume":"34","author":"Kouvari","year":"2019","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.036_bib0017","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0018","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-017-00934-5","article-title":"Genome-wide meta-analysis associates HLA-DQA1\/DRB1 and LPA and lifestyle factors with human longevity","volume":"8","author":"Joshi","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.036_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2020.04.036_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijcard.2016.09.026","article-title":"The changing face of cardiovascular disease 2000-2012: an analysis of the world health organisation global health estimates data","volume":"224","author":"McAloon","year":"2016","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.036_bib0022","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehy070","article-title":"Epidemiology of cardiovascular disease: the new ESC Atlas and beyond","volume":"39","author":"L\u00fcscher","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.04.036_bib0023","first-page":"1","article-title":"Worldwide disease epidemiology in older persons","author":"Mattiuzzi","year":"2019","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.ejim.2020.04.036_bib0024","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212609","article-title":"Therapeutic management of hyperlipoproteinemia (a)","volume":"8","author":"Kosmas","year":"2019","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.036_bib0026","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00005768-199711000-00007","article-title":"Effects of physical activity and diet on lipoprotein(a)","volume":"29","author":"Mackinnon","year":"1997","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00007256-199928010-00002","article-title":"Effects of exercise on lipoprotein(a)","volume":"28","author":"Mackinnon","year":"1999","journal-title":"Sports Med"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0028","first-page":"2","article-title":"Evidence of lifestyle modification in the management of hypercholesterolemia","volume":"9","author":"Mannu","year":"2013","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ejim.2020.04.036_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2011.01244.x","article-title":"Optimal therapy for reduction of lipoprotein(a)","volume":"37","author":"Lippi","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.036_bib0030","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2020.04.036_bib0031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10557-013-6477-6","article-title":"Underberg JA. systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values","volume":"27","author":"Rosenson","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.036_bib0032","first-page":"413","article-title":"Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.036_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","article-title":"A meta-analysis of the effect of PCSK9-Monoclonal antibodies on circulating lipoprotein (a) levels","volume":"19","author":"Cao","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.036_bib0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacl.2018.01.004","article-title":"Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: a meta-analysis of 11 randomized controlled trials","volume":"12","author":"Bai","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.036_bib0036","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Lipid and blood pressure meta-analysis collaboration (LBPMC) group. effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.036_bib0037","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00392-018-1379-z","article-title":"Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy","volume":"108","author":"Lorenzi","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2020.04.036_bib0038","article-title":"Statin therapy increases lipoprotein(a) levels","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"issue":"10155","key":"10.1016\/j.ejim.2020.04.036_bib0039","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.036_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061302","article-title":"A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey","volume":"23","author":"Oberemok","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejim.2020.04.036_bib0041","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejim.2011.06.015","article-title":"Antisense therapy in the treatment of hypercholesterolemia","volume":"22","author":"Lippi","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.036_bib0042","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-Approved oligonucleotide therapies in","volume":"25","author":"Stein","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0043","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2019.10.009","article-title":"Oligonucleotides to the (Gene) rescue: FDA approvals 2017-2019","volume":"41","author":"R\u00fcger","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"10.1016\/j.ejim.2020.04.036_bib0044","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1161\/01.CIR.98.18.1898","article-title":"Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression","volume":"98","author":"Morishita","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.036_bib0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.gt.3301434","article-title":"Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo","volume":"8","author":"Frank","year":"2001","journal-title":"Gene Ther"},{"issue":"9719","key":"10.1016\/j.ejim.2020.04.036_bib0046","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(10)60364-9","article-title":"Antisense technology to lower LDL cholesterol","volume":"375","author":"Neely","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.036_bib0047","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"issue":"9719","key":"10.1016\/j.ejim.2020.04.036_bib0048","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejim.2020.04.036_bib0049","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein b synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.036_bib0050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.036_bib0051","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"10002","key":"10.1016\/j.ejim.2020.04.036_bib0052","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.036_bib0053","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1194\/jlr.R052258","article-title":"Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans","volume":"57","author":"Graham","year":"2016","journal-title":"J Lipid Res"},{"issue":"15","key":"10.1016\/j.ejim.2020.04.036_bib0054","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"10057","key":"10.1016\/j.ejim.2020.04.036_bib0055","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejim.2020.04.036_bib0056","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.036_bib0057","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"AKCEA-APO(a)-LRx study investigators. Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.036_bib0058","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","article-title":"Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"Sahebkar","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2020.04.036_bib0059","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.04.036_bib0060","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2020-0076","article-title":"Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy","author":"Lippi","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ejim.2020.04.036_bib0061","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.036_bib0062","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0039-1687912","article-title":"Statins for preventing venous thrombosis: for or against?","volume":"45","author":"Lippi","year":"2019","journal-title":"Semin Thromb Hemost"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520301503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520301503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:46Z","timestamp":1760607166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520301503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":62,"alternative-id":["S0953620520301503"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.04.036","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}